Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- STOCK COMMENTS / EPS CHANGES
Brown-Forman (BF.B) estimates decreased at UBS. BF.B estimates were lowered through 2013. Estimates adjusted after removing the contribution of Fetzer/Hopland Assets. Maintain Neutral rating and $72 price target.Cenovus Energy (CVE) cut from Conviction Buy List at Goldman Sachs. MDR has better risk/reward at current levels. $51 price target. Discover Financial (DFS) estimates boosted at Citigroup through 2012 citing healthy loan growth expectations and a better outlook vs. banks, Citigroup said. Maintain Hold rating and $25 price target. Humana (HUM) estimates raised at Credit Suisse through 2013. Company is seeing lower costs and buying back more stock. Outperform rating and $100 price target. CarMax (KMX) estimates, target lowered at Goldman. Shares of KMX now seen reaching $34, according to Goldman Sachs. Estimates also cut, given lower expected used car sales. Neutral rating. Par Pharmaceutical (PRX) estimates lowered at UBS through 2012. Branded cost structure continues to be a drag on earnings. Maintain Buy rating and $39 price target. Qualcomm (QCOM) estimates increased at Credit Suisse through 2012. Company should continue to see strong demand from smartphone and tablet computer makers. Outperform rating and $70 price target. Synchronoss (SNCR) added to Conviction Buy List at Goldman Sachs. $39 price target. Company is leveraged to connected device growth. Under Armour (UA) estimates, target raised at FBR. Shares of UA now seen reaching $75. Estimates also increased, as fundamentals are relatively better positioned than most over the near term. Market Perform rating.
End of report.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV